Special Issue "Phage Therapy, Lysin Therapy, and Antibiotics, a Trio Due to Come"
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 34580
Interests: phage therapy; microbiology; microbial biotechnology; food microbiology; molecular microbiology; recombinant microorganisms; microbial bioactive compounds
Special Issues, Collections and Topics in MDPI journals
Special Issue in Antibiotics: Polyphenols for Friendly Handling of Microbial Control
Special Issue in Antibiotics: Frontiers in Phage Therapy
Interests: microbiology; microbial biotechnology; food microbiology; recombinant microorganisms; microbial enzymes; microbial bioactive compounds; antimicrobials; biopreservatives; biocontrol; bacteriophages; probiotics
Conventional antimicrobials have been for decades the panacea for controlling pathogenic and non-desirable bacteria, ever since the introduction of the “magic-bullet” idea by Paul Ehrlich at the beginning of the XXth century. The prescription, the missuse and most importantly the genesis of several spontaneous mutants has led to the emergence of multiresistant bacteria to antibiotics, commonly used in the treatment of current and deadly forms of diseases both in humans and other animals, to such an extent that practitioners often run out of effective prescriptions. Combination of therapies or treatments, based on different compounds is generally recognized as the more effective strategy to fight resistances. Bacteriophages (phages) are viruses that kill bacteria in a quite specific manner. Proposed a century ago, and then forgotten in western countries, phages and their lysins have emerged recently in the West as promising alternative against pathogenic bacteria, and have to walk together with the current chemotherapy including antibiotics, to design new combined strategies for the control of non-desirable bacteria, particularly those exhibiting multiresistant phenotypes.
This special issue of "Phage therapy, lysin therapy, and antibiotics, a trio due to come" deals with the more recent advances in these combined therapies. The issue welcomes various submission types, such as original research papers, short communications, reviews, case reports, and perspectives.
- Potential topics for this special issue include, but are not limited to:
- Search for phages and lysins with new mechanisms of action
- Advanced phage and lysins therapies or combined therapies with antibiotics in clinics and veterinary, including aquaculture (particularly in intensive cultures)
- Phage and lysin treatments for food-biopreservation
- Phage and lysin treatments against phytopathogenic bacteria
- Phage treatment of drinking water reservoirs
- Phage treatment of sewage waters
- Environment control of multidrug resistant bacteria: reversion of multidrug resistances
- Tailor-made phages and lysins designed for specific purposes: new genetically modified phages and lysins
- Precise formulation of phages for a variety of uses on/off clinics
- Prevention of resistances to phages and lysins
Prof. Dr. Tomas. G. Villa
Prof. Carmen Sieiro
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Phage and lysin therapies
- phage lysins
- lytic bacteriophages
- lysogenic bacteriophages
- recombinant bacteriophages
- recombinant lysins
- mutated bacteriophages
- bacterial diseases
- bacteriophage-assisted antibiotherapy
- combined therapies